Amid growing concerns over company’s sustainable performance, MannKind Corporation (NASDAQ:MNKD) has announced that it received a notice from Alfred E. Mann regarding his resignation. As per the reports, Mann decided to resign as the board member and Executive Chairman of Mannkind effective immediately.
Not long ago, company’s board of directors appointed Kent Kresa as the new Chairman of BOD. Mann was also named the Chairman Emeritus of MannKind on the same day. Post-resignation, Mann will continue to be a part of MannKind as a non-executive employee.
Insights of Matter
While talking about this update, company’s CEO Matthew Pfeffer said that Mann founded MannKind with an objective to bring unique medical innovation to the biopharmaceutical industry. Over the years, he did a fantastic job by achieving things that once looked impossible. Mann’s hard work and dedication towards finding permanent solutions for diabetes and other diseases has transformed MannKind into a world-famous brand.
His vision has made the lives of thousands of patients suffering from a broad range of diseases smooth and disease-free. From now onwards, it’s the responsibility of everyone else on the board to carry forward Mann’s ideology and ensure that his vision doesn’t fade away with the passage of time. He always worked on his dream of creating powerful products and world-class technology. There’s a long road to turn that dream into reality; however, with the kind of manpower and resources that MannKind has in today’s time, it will be done in the near future.
The new Chairman of the Board of Directors, Kent Kresa, has been on company’s board since 2004. He was named the Lead Director of MannKind in the year 2011. Over the last many years, Kresa served as the board member of Avery Dennison Corporation, General Motors Company and Fluor Corporation. He will look forward to using his subject matter knowledge and years of experience to take MannKind to all new heights in the coming months.
